Biocon partners Biomm to commercialise diabetes drug in Brazil

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

Listen to the Article (6 Minutes)

Biotechnology firm Biocon on Wednesday said it has tied up with Brazil-based Biomm SA for the commercialisation of its diabetes drug in the Latin American nation.

Under the terms of the agreement, Biocon will undertake the development, manufacturing and supply of Semaglutide (gOzempic), and Biomm will be responsible for obtaining regulatory approval and commercialization in the Brazilian market.

Biomm focuses on developing, manufacturing and commercialising complex biotech and biosimilar drug products at its production facility in Nova Lima. “Our partnership with Biomm marks another important step forward in our strategy to expand our global footprint beyond the US and Europe for Peptides,” Biocon CEO and MD Siddharth Mittal said in a statement.

Also Read: Adani family infuses ₹8,339 cr into Ambuja Cements via warrants; total investment at ₹20,000 cr

This is also in line with the growth strategy of bringing to market a portfolio of complex, GLP-1 drug-device combination products, he added. “We are confident that our collaboration with Biomm will provide patients in Brazil, who are living with diabetes, much-needed access to advanced, high-quality treatment options to help them manage the disease better,” Mittal said.

Biomm CEO Heraldo Marchezini said Brazil is the fifth country in the world with the highest incidence of diabetes, having 16.8 million adults in the age group of 20 to 79 years with the disease, and an estimated 21.5 million cases by 2030, according to the Diabetes Atlas of the International Diabetes Federation (IDF).

“We have, therefore, prioritised strategic partnerships to expand the population’s access to advanced treatments for this disease and enhance the quality of life for people,” he added. As per the IQVIA MAT data, the total addressable market opportunity of Semaglutide in Brazil is around $580 million.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow